Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep 24;100(38):e27013.
doi: 10.1097/MD.0000000000027013.

Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis

Jianxin Chen  1 , Junhui Wang  2 , Fangwei Xie  3
Affiliations

Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis

Jianxin Chen et al. Medicine (Baltimore). .

Abstract

Background: The present network meta-analysis was conducted to perform an indirect comparison among ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma (HCC) progressed on sorafenib treatment.

Methods: A systematic review through Medline, Embase, and Cochrane library was developed, with eligible randomized clinical trials been included. Hazard ratios (HRs) including progression-free survival (PFS), overall survival (OS), odds ratios of disease control rate (DCR), objective response rate (ORR), and adverse events were compared indirectly with network meta-analysis using random model in software STATA version 13.0.

Results: A total of 4 randomized clinical trials including 2137 patients met the eligibility criteria and enrolled. Indirect comparisons showed that there was no statistical difference observed in the indirect comparison of PFS, OS, ORR, or DCR among agents of regorafenib, cabozantinib, and ramucirumab in advanced HCC patients with elevated α-fetoprotein (AFP) (400 ng/mL or higher). However, in patients with low-level AFP (lower than 400 ng/mL), regorafenib was the only agent associated with significant superiority in OS, compared with placebo (hazard ratio 0.67, 95% CI, 0.50-0.90).

Conclusions: The present network meta-analysis revealed that there might be no statistical difference observed in the indirect comparison of PFS, OS, ORR, or DCR among regorafenib, cabozantinib, or ramucirumab in advanced HCC patients with elevated AFP (400 ng/mL or higher). However, in patients with low-level AFP (lower than 400 ng/mL), regorafenib might be associated with significant superiority in OS, compared to placebo, which need further investigation in clinical practice.

PubMed Disclaimer

Conflict of interest statement

The authors have no funding and conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Study selection procedure with PRISMA flow diagram. PRISMA = Preferred Reporting Items For Systematic Reviews and Meta-analyses.
Figure 2
Figure 2
Network of the comparisons.
Figure 3
Figure 3
Direct and indirect comparisons for PFS among Ram (ramucirumab), Reg (regorafenib), Cab (cabozantinib), and PLA (placebo). PFS = progression-free survival.
Figure 4
Figure 4
Direct and indirect comparisons for OS among Ram (ramucirumab), Reg (regorafenib), Cab (cabozantinib), and PLA (placebo). OS = overall survival.
Figure 5
Figure 5
Direct and indirect comparisons for ORR (A) and DCR (B) among Ram (ramucirumab), Reg (regorafenib), Cab (cabozantinib), and PLA (placebo). DCR = disease control rate; ORR = objective response rate.
Figure 6
Figure 6
Direct and indirect comparisons for PFS (A and C) and OS (B and D) by AFP level (A and B for low-level AFP; C and D for high level AFP), among Ram (ramucirumab), Reg (regorafenib), Cab (cabozantinib), and PLA (placebo). AFP = α-fetoprotein; OS = overall survival; PFS = progression-free survival.
Figure 7
Figure 7
Treatment comparison for SAEs (A), FAEs (B), and TEs (patients suffered dose reduction, (C); death during the therapy or within 30 days of treatment discontinuation, (D) (ORs, 95% CI). FAEs = fatal adverse events; OR = odds ratio; SAEs = severe adverse events; TEs = treatment events.
Figure 8
Figure 8
Treatment comparison for elevated ALT (A), hypertension (B), vomiting (C), and fatigue (D) at all grades (ORs, 95% CI). ORs = odds ratios.
Figure 9
Figure 9
Treatment comparison for elevated ALT (A), hypertension (B), vomiting (C), and fatigue (D) at high grade (ORs, 95% CI). OR = odds ratio.
Figure 10
Figure 10
Funnel plot for the detection of publication bias (Ram, ramucirumab; Reg, regorafenib; Cab, cabozantinib; PLA, placebo).
See this image and copyright information in PMC

References

    1. Akinyemiju T, Abera S, Ahmed M, et al. . C. Global Burden of Disease Liver Cancer. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol 2017;3:1683–91. - PMC - PubMed
    1. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127: (Suppl 1): S35–50. - PubMed
    1. de Martel C, Maucort-Boulch D, Plummer M, Franceschi S. World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma. Hepatology 2015;62:1190–200. - PMC - PubMed
    1. Bruix J, Sherman M. American Association for the Study of Liver. Management of hepatocellular carcinoma: an update. Hepatology 2011;53:1020–2. - PMC - PubMed
    1. European Association For The Study Of The Liver, European Organisation For Research And Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908–43. - PubMed

Publication types

MeSH terms